Document is current
Any future updates will be listed below
-
Authors
El Abiead, Yasin https://orcid.org/0000-0003-4392-7706
Strobel, Michael
Payne, Thomas
Fahy, Eoin https://orcid.org/0000-0003-3196-522X
O’Donovan, Claire
Subramamiam, Shankar
Vizcaíno, Juan Antonio https://orcid.org/0000-0002-3905-4335
Yurekten, Ozgur
Deleray, Victoria
Zuffa, Simone https://orcid.org/0000-0001-7237-3402
Xing, Shipei
Mannochio-Russo, Helena
Mohanty, Ipsita https://orcid.org/0000-0003-0894-4770
Zhao, Haoqi Nina https://orcid.org/0000-0003-3908-630X
Caraballo-Rodriguez, Andres M.
P. Gomes, Paulo Wender
Avalon, Nicole E. https://orcid.org/0000-0003-3588-892X
Northen, Trent R. https://orcid.org/0000-0001-5903-1870
Bowen, Benjamin P. https://orcid.org/0000-0003-1368-3958
Louie, Katherine B. https://orcid.org/0000-0002-6787-7558
Dorrestein, Pieter C. https://orcid.org/0000-0002-3003-1030
Wang, Mingxun https://orcid.org/0000-0001-7647-6097
- License Information
-
More Information
Article History
Received: 20 February 2025
Accepted: 14 May 2025
First Online: 24 May 2025
Competing interests
: P.C.D. is an advisor and holds equity in Cybele, BileOmix, and Sirenas and a Scientific co-founder, and advisor, received income and/or holds equity to Ometa, Enveda, and Arome with prior approval by UC-San Diego. P.C.D. also consulted for DSM animal health in 2023. M.W. is a co-founder of Ometa Labs LLC. The remaining authors declare no competing interests.
